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7SUMMARY
This thesis consists of four studies examining inherited variants in cytokine genes 
and their pathogenetic impact in rheumatoid arthritis (RA), multiple myeloma (MM) 
and B-cell non-Hodgkin’s lymphoma (B-NHL). 
In the first study, We established a method to investigate functional variants in the 
CHI3L1 gene, encoding the pro-inflammatory YKL-40 protein. We genotyped eight 
single nucleotide polymorphisms (SNPs) in a cohort of 308 RA patients and a 605 
healthy controls (HC) and subsequently measured serum levels of YKL-40. We 
found strong association between serum YKL-40 and the CHI3L1 -131 C/G 
(rs4950928) SNP in RA (p=2.4e-08) and HC (p<2.2e-16). We did however not 
detect association between genotypes and risk of RA. In the second study, We
expanded the search for pathogenetic SNPs. The impact of thirteen SNPs was 
investigated in a cohort of 348 MM patients and 355 HC. We discovered an 
association between the TNFA -238A (rs361525) allele and decreased risk of MM 
(OR=0.51 (0.29-0.86)). Our findings also suggested a prognostic effect of TNFA and 
IL10 genotypes, whereas we did not find evidence for an effect of the CHI3L1
(rs4950928) SNP. Cytokines interact in complex networks, and we aimed to 
establish a model for studying gene-gene interactions. Our power to study such 
interactions were limited due to the size of our cohorts, however we suggest a 
prognostic effect of interactions between IL6 and IL10 and TNFA and IL4. To 
include a functional approach, we determined the expression of such interacting 
genes in normal and malignant B-cells. The expression pattern suggests that these 
genes play a role in different stages of the pathogenetic process, and we were able to 
use CHI3L1, IL6 and IL10 expression to predict prognosis, according to the TC 
classification, in a retrospective dataset of 414 MM patients. In the third study we 
included 50 SNPs in our screening. Selection of SNPs reflected the findings from 
the two first studies and recent genome wide association studies (GWAS). 
Genotyping was performed on a custom designed SNP array, and we developed a 
method for DNA extraction from the formalin fixed bone marrow samples we had 
available. 355 B-NHL patients and 307 HC were included. We confirmed 
associations from recent GWAS and proposed novel associations. Amongst notable 
findings, the CHI3L1 (rs4950928) was related to outcome (HRCG = 2.04 (1.17-3.54))
in follicular lymphoma. Interaction was observed between IL-4 and IL-10 related 
genes and subsequently explored on gene expression level using normal B-cell 
subpopulations and lymphoma cells. The expression pattern of IL10, IL10RB and 
IL4R was indicative of an effect in the stepwise oncogenesis believed to precede B-
cell lymphomas. In light of these complex findings and the vast amount of studies 
published in parallel with our studies being carried out, we decided to thoroughly 
review the literature and described studies of genes associated with lymphoma risk 
8and prognosis as reported in the fourth study. We used this as a platform for a 
discussion of the need for new candidate gene studies, whole genome studies and 
suggested that studies should be consortium driven to ensure statistical power in 
order to investigate gene-gene interactions. We also suggest, that the functional 
aspect of such proposed pathogenetic genes are studied. We have taken the first 
steps towards designing model systems for the investigation of in vivo as well as in 
vitro function of these proposed pathogenetic genes and we believe that this 
combined approach in the near future will bring us a more detailed knowledge of the 
complex biology in B-cell diseases eventually leading to a more rational prognostic 
classification, improved treatment strategies and the possibility of real personalized 
medicine.
9RESUME (DANSK)
Afhandlingen består af fire studier som undersøger udvalgte nedarvede varianter i 
gener for inflammatoriske cytokiner og deres patogenetiske betydning ved 
rheumatoid artritis (RA), myelomatose (MM) og B-celle non-Hodgkin’s lymfom (B-
NHL).
I det første studie etablerede vi metoden til genotypning af single nucleotide 
polymorphisms, (SNP's) og tog derefter udgangspunkt i CHI3L1 genet, der koder for
det pro-inflammatoriske protein YKL-40. Vi genotypede 8 SNPs i CHI3L1 genet i 
en kohorte af 308 RA patienter og 605 raske kontroller. I undersøgelsen målte vi 
samtidig serumniveauer af YKL-40 og fandt disse stærkt associeret til CHI3L1 -
131C/G (rs4950928) i RA  (p=2.4e-08) og i kontroller (p<2.2e-16). Vi kunne ikke
påvise en sammenhæng mellem genotyper og risiko for RA. I det andet studie 
udvalgte vi i alt tretten funktionelle SNP's. Vi genotypede 348 MM patienter og 355 
kontroller og fandt en association mellem TNFA -238A (rs361525) og nedsat 
sygdomsrisiko (OR=0.51 (0.29-0.86)). Vi kunne desuden sandsynliggøre en
sammenhæng mellem TNFA og IL10 genotyper og sygdommens prognose. 
Inflammatoriske cytokiner interagerer i netværk, og vi etablerede derfor en model til
at studere gen-gen interaktioner. Med de begrænsninger vi havde i form af et relativ 
lille patient materiale, kunne vi vise en mulig sammenhæng mellem prognose og 
interaktion mellem IL6 og IL10 samt TNFA og IL4 genotyper. Vi undersøgte 
derefter ekspression af de pågældende gener i normale B-celler samt i MM celler og 
fandt et ekspressionsmønster som antyder en betydning af disse gener ved udvikling 
af den maligne celleklon. Vi inkluderede yderligere et retrospektivt datasæt, og 
kunne vise at CHI3L1, IL6 og IL10 ekspression er prognostisk ud fra TC 
klassifikationen. I det tredje studie genotypede vi 355 B-NHL patienter og 307 
kontroller for 50 SNPs. Vi etablerede først en metode til at oprense DNA fra 
formalinfikseret væv og designede derefter en custom SNP array til genotypning. De 
udvalgte SNPs afspejlede resultater fra de 2 første studier, og vi inkluderede 
yderligere SNPs ud fra genome wide association studies (GWAS). Vi bekræftede 
tidligere påviste sammenhænge mellem såvel sygdomsrisiko og overlevelse og 
antydede en ny sammenhæng mellem CHI3L1 (rs4950928) og follikulært lymfom
(HRCG = 2.04 (1.17-3.54)). Gen-gen interaktions analyse viste en mulig kombineret 
effekt af gener af betydning for IL-4 og IL-10 og disse interaktioner blev 
efterfølgende undersøgt på gen ekspressions niveau med fund af forskellig 
ekspression af IL10, IL10RB og IL4R mellem diskrete B-celle subpopulationer og 
lymfomceller. Dette fund antyder en effekt af disse gener i den trinvise 
onkongenese, man formoder sker i udvikling af disse kræftceller. Baseret på det 
komplekse billede vi observerede i vores studier og den litteratur, der sideløbende er 
publiceret, foretog vi en litteraturgennemgang og beskrev i det fjerde studie den 
10
foreliggende litteratur vedrørende gener associeret til sygdomsrisiko og overlevelse. 
Vi diskuterede behovet for nye consortium drevne studier med den nødvendige 
statiske power til såvel kandidatgen, helgenom og gen-gen interaktioner. Vi 
argumenterede for at genetisk screening for nedarvede patogenetiske varianter 
medfører, at disse efterfølgende undersøges funktionelt i såvel in vivo som in vitro 
modelsystemer. Målet er at erhverve ny biologisk viden om B-celle sygdommene,
og vi arbejder allerede nu med modeller for såvel in vitro og in vivo funktionelle 
aspekter af disse genetiske variationer. Perspektivet er at denne viden kan anvendes
til at designe ny prognostiske systemer samt til at skræddersy behandlingen for den 
enkelte patient og dermed opnå egentlig ”personalized medicine”.
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PUBLICATIONS
This Ph.D. thesis is based on four manuscripts aimed for publishing in international 
peer-reviewed journals. Paper I and IV are published. Paper III is accepted for 
publications. Paper II is under review.
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Bødker JS, Johansen P, Dybkær K, Bøgsted M, Vogel U, Johnsen HE, Vangsted A. 
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PAPER III
Inherited inflammatory response genes are associated with B-cell non hodgkins
lymphoma risk and survival. Nielsen KR, Steffensen R, Bendtsen MD, Rodrigo-
Domingo M, Baech J, Haunstrup TM, Bergkvist KS, Schmitz A, Bødker JS, 
Johansen P, Dybkær K, Bøgsted M, Johnsen HE. Accepted for publication in
PlosOne
PAPER IV
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JS, Dybkær K, Baech J, Bøgsted M, Johnsen HE. Leuk Lymphoma. 2015 Jul 7:1-
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HYPOTHESIS AND AIMS
HYPOTHESIS
Inherited genetic variation in cytokine genes are of pathogenetic impact in B-cell 
diseases and could affect disease risk and outcome. 
This hypothesis was tested through the following aims. Results and conclusions are
reported in Paper I-IV.
AIMS
 Establish a method for genotyping of functional variants in cytokine genes.
 Determine the frequency of functional cytokine genes in patients with B-
cell diseases and a healthy control group.
 Determine the association between functional cytokine gene and outcome 
in B-cell diseases.
 Determine the interaction between cytokine genes in relation to disease risk 
and outcome.
 Determine the gene expression patterns of pathogenetic genes in normal 
and diseased B-cells.
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ABBREVIATIONS
ABC-DLBCL Activated B-cell diffuse large B-cell lymphoma.
ACR American college of rheumatology
APRIL A proliferation-inducing ligand.
BCR B-cell receptor.
BLyS/BAFF B-cell activating factor.
BM Bone marrow.
B-NHL B-cell non- Hodgkin’s lymphoma.
CB Centroblast.
CC Centrocyte.
CHI3L1 Chitinase-3-like protein 1
Chr Chromosome.
CNV Copy number varation
CSR Class-switch recombination.
DLBCL Diffuse large B-cell lymphoma.
FDC Follicular dendritic cell.
FL Follicular lymphoma.
GC Germinal center.
GCB-DLBCL Germinal center B-cell diffuse large B-cell lymphoma.
GWAS Genome wide association study.
HC Healthy control.
HDT/ASCT High dose therapy with autologous stem cell transplantation.
HGF Hepatocyte growth factor.
IFN Interferon.
Ig Immunoglobulin.
IgH Immunoglobulin heavy chain.
IgL Immunoglobulin light chain.
IL Interleukin.
LD Linkage disequilibrium
LN Lymph node.
LT Lymphotoxin
LTi Lymphoid tissue inducer cell.
MIF Macrophage inhibitory factor.
MGUS Monoclonal gammopathy of undetermined significance.
MM Multiple myeloma.
M  Macrophage.
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
OS Overall survival
PC Plasma cell.
RA Rheumatoid arthritis.
14
SHM Somatic hyper mutation.
SNP Single nucleotide polymorphism.
TC Translocation and cyclin D classification.
TGF Transforming growth factor.
TLR Toll-like receptor.
TNF Tumor necrosis factor.
YKL-40 Chitinase-3-like protein 1
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INTRODUCTION
GENERAL INTRODUCTION
Inherited genetic variation in cytokine genes affects gene function in B-cells and the 
lymph node microenvironment
1–6
. These functional variants could be part of the
sustained inflammation observed in chronic inflammatory disorders as rheumatoid 
arthrtitis (RA) and be involved in the pathogenesis in cancers by promoting
malignant transformation and the proliferation and evolution of malignant clones as 
illustrated in Figure 1 (Paper IV, Figure 2)
Figure 1. The effect of cytokine signaling in the proliferation of malignant B-cell clones. Sustained 
activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) enhances autocrine 
signaling by the lymphoma cells. Interleukin (IL)-6 is expressed by antigen presenting cells in the LN –
and by B-cells, whereas IL1B, IL-2, IL-3, and tumor necrosis factor alpha (TNF-α) and YKL-40 are 
produced by immune cells in the LN. The combined effect of paracrine stimulation and autocrine loops 
stimulates to uncontrolled proliferation
1–6
. 
Cytokines play an important role in the proliferation and differentiation of normal B-
cells
7,8
. The lymph node (LN) microenvironment include lymphoid tissue inducer 
16
cells (LTi), T follicular helper cells (Tfhs), follicular dendritic cells (FDCs), 
macrophages (MΦ), stromal cells, and T-cells
9,10
. These cells secrete various pro-
and anti-inflammatory cytokines that orchestrate B-cell development
11
.
Dysregulation of B-cells is a major pathogenetic factor in RA
12
. RA affects 1% of 
the population and is known to be associated with more than 2 fold increase risk of 
developing B-cell non Hodgkin’s lymphoma (B-NHL), possibly due to the chronic 
B-cell activation and stimulation by inflammatory mediators
13
. Hematological 
malignancies account for 10% of all malignant diseases; 95% of these are of B-cell
origin, with B-NHL and multiple myeloma (MM) accounting for more than 50% of 
the cases
14,15
. Gene expression analyses of malignant B-cells and the tumor 
microenvironment have classified both B-NHL and MM in discrete groups in 
relation to prognosis; these findings argue that a pro-inflammatory milieu have a 
negative effect on disease risk and outcome
16,17
. Suggestive evidence points to a 
combined effect of these mediators interacting in inflammatory networks
3,18
. These 
genetic differences could even act as primary genetic hits or alter the cell´s response 
to anti-inflammatory drugs or chemotherapy
19–22
. For these reasons, inherited 
functional genetic variation is thought to be of pathogenetic impact in B-cell 
diseases. Investigation of such pathogenetic variations using methods as hypothesis 
driven candidate gene studies and genome wide association studies (GWAS) 
combined with gene-gene interaction analyses may prove useful as a screening 
approach, with the goal of identifying candidate genes for subsequent functional 
analyses.
17
THE B-LYMPHOCYTE
B-cells are the central mediators of adaptive humoral immunity, however, the 
function of B-cells have been recognized only since the early 1970s
23,24
. B-cells are 
capable of differentiating into long lasting plasma cells (PCs) responsible for the 
generation of high affinity antigen-specific antibodies (immunoglobulins (Igs))
25
involved in innate immune responses through toll like receptor (TLR) activation. 
They play an important role in antigen presentation and immune regulation
26,27
.
Mature B-cells are defined by the expression of membrane-bound immunoglobulin 
molecules (the B-cell receptor (BCR)). The variability in the BCR repertoire is the 
result of gene recombination at the variable (V), joining (J) and diversity (D) gene 
segments (V(D)J recombination). The process ultimately results in novel amino acid 
sequences in the antigen binding site of the Igs and in an Ig composed of two 
immunoglobulin heavy (IgH) chains and two immunoglobulin light (IgL) chains 
(either κ or λ)
28
. The development and differentiation of B-cells is dependent on the 
microenvironment in the bone marrow (BM) and LN
6
. In mice, early B-cell 
development depends crucially on interleukin (IL)-7; however, the cytokine profile 
required for shaping the human B-cell compartment remains elusive
25
. B-cell 
development is initiated by DH to JH rearrangement at the IgH locus on chromosome 
(Chr) 14
29
. Surviving pre-B-cells rearrange the VL to JL genes at the κ locus at Chr 2 
and, if unsuccessful, the λ locus at Chr 22. The mature naïve transistional B-cells are 
critically dependent on tumor necrosis factor (TNF) family cytokines, B-lymphocyte 
stimulator (BLys/BAFF) and to some extend A Proliferation Inducing Ligand
(APRIL) for survival signals
8
. The B-cell now enters the secondary lymphoid 
organs
30
. When encountering an antigen, T-cells stimulate the mature naïve B-cells 
to proliferation; these either form short lived IgM producing PCs or initiate the
germinal center (GC) reaction. GC consists of B-cells (termed centrocytes (CC) and 
centroblasts (CB)), FDCs and Tfhs. The CBs undergo DNA editing in terms of
somatic hyper mutation (SHM) and class-switch recombination (CSR)
31
. The GC 
reaction is dependent on a number of growth factors and cytokines; the exact 
functions of these are however currently not fully understood. The process of CSR
is dependent on both cell mediated signaling and cytokine signaling from Tfh and 
FDCs producing  IL-2, IL-4, IL-10, IL-12, IL-13, IL-17, IL-21, interferon gamma
(IFNγ), transforming growth factor beta (TGBβ) and TNFα responsible for survival
and proliferation signals and for shaping the antibody repertoire
32
– see Figure 2
(Paper IV, Figure 1).
33
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Figure 2. Cytokines shape the normal B-cell differentiation 
The somatically mutated, isotype switched B-cells then complete the transition into 
antibody secreting PCs or memory B-cells. A number of cytokine stimuli, most 
notable IL-4 and Il-10, promote memory B-cell differentiation
34,35
.  Persisting 
antigenic stimulation, cytokines and TLR signaling may drive memory B-cells into 
PC differentiation
36,37
. PC differentiation is enhanced by cytokines and IL-2, IL-5, 
IL-6, IL-13 and most prominently IL-21, whereas TNF family cytokines and IL-6 is 
important for long term PC survival
38
.
19
THE B-CELL DISEASES
RHEUMATOID ARTHRITIS
RA is a chronic systemic autoimmune disorder that affects approximately 1% of the 
population. The characteristics of the disease are destructive polyarthritis and signs 
of systemic inflammation
39
. RA was for a long time considered a T cell driven 
disease, but clearly B cells play an important role in the RA pathogenesis and RA is 
associated with a more than two fold increase in the risk of developing B-
NHL
13,40,41
. The synovial cellular infiltrates found in RA resembles a GC structure 
releasing autoantibodies and cytokines, and the B cells support autoreactive T cells 
by more than 1000-fold efficiency compared to other professional antigen presenting 
cells
42
. Autoantibodies form immune complexes that contribute to increased 
inflammation as well as activation of the complement system and are considered a 
predictor for increased joint destruction
43
. Twin-studies have estimated that genetic 
factors accounts for about 60% of the disease risk, however, less than half of these
can be attributed to already identified genetic loci. The strongest genetic association
to RA is with genes within the HLA locus and the tyrosine phosphatase non receptor 
type 22 (PTPN22)
44
. Susceptibility genes associated with RA such as PTPN22 have 
been shown to affect BCR signaling pathways
12
, and a recent study has found the 
BACH2 transcription factor loci to be highly associated with RA risk
45
. There even 
seems to be an association between post treatment B-cell phenotypes in the synovial
infiltrate and clinical treatment efficiency
12,45
. Cytokines are the major factor in the 
pathogenesis of RA, illustrated by the effect of TNF inhibiting drugs in the RA 
treatment. Among potential risk loci are the chitinase 3-like 1 (CHI3L1) gene 
encoding the YKL-40 protein. YKL-40 contains HLA-DR4 binding motifs, and has 
been suggested to function as an autoantigen in RA
46
. Variation in genes encoding 
signal transducer and activator of transcription (STAT4), cytotoxic T-lymphocyte-
associated protein 4 (CTLA4), Fc gamma receptor III-a (FCGR3A), interleukin-6 
signal transducer (IL6ST), interleukin-2 receptor alpha (IL2RA), interleukin-2 
receptor beta (IL2RB), IL21, IL23 and cluster of differentiation 40 (CD40) are
associated with RA. Recent GWAS data reported TNF receptor-associated factor 1
(TRAF1) the third most strongly RA-associated locus. The TRAF1 protein links 
TNFα to downstream signaling networks. Even though recent GWAS studies have 
identified novel risk genes, future studies are necessary to elucidate the remaining 
unknown genetic factors associated with RA.
44,47
The effect of gene-gene interaction 
have also only been analyzed in a limited number of studies and needs further 
investigation
48,49
.
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MULTIPLE MYELOMA 
MM is a clonal B-cell neoplasm that affects terminally differentiated B-cells. The 
disease is characterized by BM infiltration of malignant plasma cells, monoclonal 
protein in serum and/or urine and the presence of lytic bone lesions. A monoclonal 
gammopathy of undetermined significance (MGUS) or smouldering multiple 
myeloma precedes MM in most cases. Here, precursor conditions are characterized 
by varying levels of monoclonal protein in the blood and/or urine and the presence
of clonal plasma cells in the BM
50
. Patient’s ≤ 70 years of age are usually treated 
aggressively with high-dose treatment with autologous stem cell support
(HDT/ASCT). Despite intensive treatment strategies the disease is still regarded 
incurable with a median survival time of 5 years after diagnosis. However,
significant variations in treatment outcomes are seen, even in patients with equal 
prognostic markers
51
. Since family histories of either MM or other lymphoid 
malignancies are known risk factors, and racial and ethnic variations in disease risk 
are observed, an inherited genetic component affecting the risk of MM development
is suggested. This has been studied intensively, primarily based on knowledge from 
cytokines known to stimulate the growth of PCs. Findings are overall contradictory
and most studies until now have been small in sample sizes
52,53
. The interleukin-1 
beta (IL1B) gene seems to be rather consistently associated with MM
54
, whereas 
findings with respect to the TNFA and IL10 genes have been more contradictory
55–59
. 
The IL6 gene has only been limitedly studied
59–62
, and the IL4 and CHI3L1 genes 
have not yet been investigated in relation to MM. To further complicate the picture, 
recent GWAS studies have not been in consistence with earlier findings, and 
confirmatory and novel screening studies are still needed
63
. Other possible risk 
factors for MM are immunodeficiency and autoimmune diseases, however, data on 
these risk factors remain contradictory
64
. Malignant plasma cells arise from a 
myeloma propagating cell with the capacity to self renew and proliferate. An 
initiating event is thought to be translocations leading to cyklin-D deregulation, 
plasma cell proliferation and hyperdiploidia
65
. However, inherited genetic variation 
might precede these translocations
66
. Secondary hits drive disease progression, and 
MM cells express genes that are target of nuclear factor kappa-light-chain-enhancer 
of activated B cell activation (NF-κB) which explains for the dependence on BM 
microenvironment. As a consequence of accumulating genetic alterations,
constitutive activation of these pathways take over and, in the case of plasma cell 
leukemia, make these cells less dependent on growth factors. MM is often a mix of 
3-6 clones with different mutational status; in average, every clone has 35 mutations. 
Gene expression profiles have shown that expression of NF-κB-related genes are 
associated with a discrete prognostic group emphasising the importance of these 
pathways
67
. Growing evidence suggests, that the interaction between normal host 
cells, genetically altered premalignant cells and inflammatory mediators in the 
microenvironment are indispensable for the proliferation of the malignantly 
transformed clone. The BM microenvironment plays an important role in 
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differentiation, drug resistance, proliferation and survival of the malignant cells. 
Genes encoding key inflammatory mediators have been associated with disease risk 
and outcome
52,53
. Growth factors such as IL-1β, IL-4, IL-6, IL-10, YKL-40, 
BLys/BAFF, APRIL, TGFβ and insulin-like growth factor-1 (IGF-1) are regulated 
through paracrine as well as autocrine pathways. In vitro proliferation of MM cells 
are supported by primarily IL-6. Osteoclasts and osteoblasts produce IL-6 and YKL-
40. IL-1β produced from MM cells further upregulates IL-6 production and NF-κB 
activation
68–70
. TNFα and lymphotoxin alpha (LTα) are both potent inducers of IL-6 
production and are shown to stimulate growth of malignant plasma cells
71
.
B-CELL NON HODGKIN’S LYMPHOMA
B-NHL is a malignant disease accounting for 80-85% of all malignant lymphomas 
in the western world and roughly 5% of all cancers
14,72
with a slightly increasing 
incidence
73
. B-NHL is caused by malignant transformation of mature B 
lymphocytes; the two most common subtypes are diffuse large B-cell lymphoma 
(DLBCL) and follicular lymphoma (FL). These subtypes account for 35% and 20% 
of all cases, respectively
74
. The etiology of B-NHL remains unknown; however, 
among known risk factors, immune suppression is the best described and 8% of 
patients with B-NHL display autoimmune manifestations suggesting immune
dysregulation
75–77
. Family- and twin studies do not support strong penetration by a 
single gene. Increased lymphoma risk is probably caused by inheriting a deleterious 
genotype, which include a number of genetic variations distributed over a number of 
risk alleles that combine to form a high-risk phenotype
78–81
. A large number of 
studies have investigated these inherited genetic risk factors. However, lack of 
consistence between studies has been a major problem for interpretation of these 
findings. Moreover, recent GWAS studies are pointing in different directions and 
only show limited consistence with earlier candidate gene studies. Gene-gene 
interactions have only been studied for a limited number of genes and functional 
approaches are lacking. As reported in Paper IV, TNFA, IL10 and HLA loci have 
been relatively constitutively associated with disease risk
82–95
and TNFA genotypes 
with outcome
96–99
,however, most findings still need further confirmation.
DIFFUSE LARGE B-CELL LYMPHOMA 
DLBCL is characterized by autonomous growth of B-cells that harbor a number of 
different genetic alterations; typically 30-100 genetic lesions pr case but displaying 
great variability between individual patients. In general, around 50% of patients with 
DLBCL are cured by conventional chemotherapy and a minority of relapsed patients 
is cured by HDT/ASCT
100
. DLBCL occur in two major prognostic subtypes; 
germinal center B-cell–like (GCB)-DLBCL and activated B-cell–like (ABC)-
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DLBCL
101–103
. The two subtypes present different genetic profiles based on “cell of 
origin” classifications and oxidative phosphorylation genes
104,105
.
The mutational landscape of DLBCL is identified primarily by SNPs and copy 
number variation (CNV) with few translocations being present. Compared to most 
other malignancies, tumor protein p53 (TP53) mutations are rare. However, lesions 
in histone/chromatin modification enzymes and acetyl transferases are found in 
more than 40% of cases leading to increased B-cell lymphoma 6 (BCL-6) activity 
and decreased p53 activity
106
. Around 50% of DLBCL cases harbor translocations 
placing the anti-apoptotic B-cell lymphoma 2 gene (BCL2) (t14;18) or pro 
proliferative Cyklin-D (t11;14) gene under control of the IgH promoter. Recently, 
gene expression profiles of the tumor microenvironment were used to stratify 
patients in relation to outcome in DLBCL; these studies showed that a 
monocyte/macrophage and matrix protein signature (Stromal-I) was related to a 
favorable outcome whereas a an microenvironment characterized by angiogenesis 
and endothelial cells were associated with a dismal outcomes
11,107–109
. Cytokines
seems to play a significant role in DLBCL. Recent studies reported pre-treatment 
markers, here among interleukin-1 receptor antagonist (IL-1RA), IL-6, IL-8, IL-10, 
IFN-γ, IFN-gamma-inducible protein 10 (IP-10), vascular endothelial growth factor 
(VEGF), soluble interleukin-2 receptor (sIL-2R), monokine induced by gamma 
interferon (MIG), and IL-12, hepatocyte growth factor (HGF), and macrophage 
inflammatory protein 1 alpha (MIP-1α), associated with DLBCL.
110–112
High IL-10 
is associated with decreased overall survival (OS) possibly through an JAK2 
/STAT3 pathway leading to proliferation
113
. Serum levels of TNFα, IL-6 , VEGF, 
basic fibroblast growth factor (bFGF), YKL-40, IL-8, IP-10 and sIL-2R have 
similarly been linked to outcome
114–118
. Malignant B-cells have also been shown to 
express cytokine genes, however, for the DLBCL subgroup this topic remains 
largely unknown
119
.
FOLLICULAR LYMPHOMA
FL is mostly a low grade lymphoma with an indolent clinical course and a median 
survival of 10 years
14
. The disease is often disseminated at time of diagnosis and is
at that stage incurable with chemotherapy. A fraction of FL will transform into a 
DLBCL like lymphoma with a dismal prognosis. The vast majority of FL cases 
exhibit the (14;18) translocation, which up-regulates BCL-2 expression. 
Translocation of the BCL2 locus to the Igκ locus t(2;18) or the Igλ locus t(18;22) 
may also occur. The BCL-2 upregulation allows for escape from apoptosis. B-cells 
harboring the t(14;18) translocations are seen in a small fraction of B-cells in >50% 
of healthy persons - of which most do not develop lymphoma after follow up
120
, 
pointing to the fact that single translocations are neither necessary nor sufficient for 
causing overt malignant disease. FL may in fact originate from a pre-B-cell 
harboring the initiating translocation, acquiring secondary transforming events as 
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p53 mutations and chromosomal gains/deletions
106
. FL cells are difficult to grow in 
vitro and this gave a clue to the need of stimuli from the tumor environment,
primarily activating NF-κB pathways, providing growth signals to the FL cells
121
. 
Studying the LN microenvironment in FL revealed two signatures of prognostic 
impact. The Immune response-I signature rich in T-cells predicted a favorable 
outcome compared with an LN environment with macrophages and dendritic cells –
Immune response-II – which was associated with a poor outcome. This finding 
argues that a pro-inflammatory milieu has a negative effect and also suggests, that 
T-cells may play a role in inhibiting tumor progression
122–124
. Cytokines acts as 
proliferation and growth signals for FL cells. Increased levels of tumor necrosis 
factor receptor 2 (sTNFR2) and vascular endothelial growth factor receptor type 2
(sVEGR2) can forego clinical FL by more than 8 years
125
. Serum level of IL-10 and 
TNFα
112,125
, IL-2R, IL-1RA, HGF, MIG and MIP-1a is associated with FL at time of 
diagnosis
110
whereas serum levels of IL-2R, IL-1RA and chemokine (C-X-C motif) 
ligand 9 (CXCL9)
126
,    TGF-β and VEGF
127
have all been associated with disease 
outcome. 
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GENETIC POLYMORPHISMS AND 
GENE-GENE INTERACTIONS
SNPs are defined as evolutionarily stable, single nucleotide DNA sequence 
variations that occur in at least 1% of the general population. The human genome 
contains more than 10
7
SNPs, which make up 90% of all human genetic variations. 
Functional SNPs located in the promoter region can affect transcription factor 
binding which changes the expression of the gene – see Figure 3 (Paper IV, Figure
3A). If the SNP is located in the coding regions it could result in a change in protein 
structure and function, or introduce a stop codon, leading to a truncate protein – see 
Figure 4 (Paper IV, Figure 3B). SNPs located in non-coding regions can affect gene 
splicing – see Figure 5 (Paper IV, Figure 3C). SNPs can also interfere with
microRNA binding or long non-coding RNA binding sites and even induce 
epigenetic modification
128
. 
Figure 3. SNP located in promoter region.
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Figure 4. SNP located in coding region of the gene.
Figure 5. SNP located in the non-coding region of the gene.
In genes that encode inflammatory response proteins, SNPs are estimated to be
responsible for up to 75% of protein variation
129
. By their functional effects, these 
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SNPs can affect the inflammatory response through paracrine and autocrine 
secretion of inflammatory cytokines. Apart from these indirect effects, SNPs may 
affect cells directly with a genetic hit that affects the tumorigenesis process
20,21
.
Furthermore, recent studies have shown that genetic hits in progenitor cells can lead 
to epigenetic changes that affect the phenotypes of mature cells
21
. Recently, growing 
interest has focused on the fact that inflammatory mediators work in complex 
networks. Thus, studying single SNPs is less informative than previously thought 
and the genetic of cancer cells and the cytokine network in the tumor 
microenvironment is viewed with increasingly complexity and simple mechanisms 
is no longer suspected
130,131
. Cytokine genes may interact to cause an epistatic effect. 
Epistasis is a non-linear association between genotype combinations and the clinical 
phenotype. Genetic predisposition to B-cell diseases may be caused by interactions 
between loci or genes that individually show little or no contribution to risk, further 
complicating the functional aspect of genetic variation in inflammatory response 
genes
132,133
.
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FUNCTIONAL GENETIC VARIATION IN 
CYTOKINE GENES 
Controversy still exists regarding the exact functional effect of SNPs in cytokine
genes. Some –but not all- loci associated with risk and prognosis in hematogical 
malignancies have been investigated with respect to their functional properties using 
rather different techniques and methods; the topic has recently been reviewed by 
Smith et al
134
. Amongst the most intensively studied genes are the IL6 gene and, to a 
lesser extent, the IL6R gene. The genetic variation in the IL6 gene is restricted to the 
promoter region and the RefSNP cluster ID number (rs) 1800795 polymorphism has 
been intensively studied. Luciferase reporter assays have showed a 2.4-3.6 fold 
increase in expression from the G allele, however a number of in vivo and in vitro 
studies have not been able to show a simple association between alleles and gene 
activity. More distal promoter SNPs may be responsible for most of the functional 
genetic variation in the IL6 gene; this seems only to affect certain cell types and 
certain inflammatory condition adding another layer of complexity to these 
functional genetic variants
128
. The IL10 locus has also been studied as the promoter 
region harbors several SNPs. The rs1800896, rs1800871 and rs1800872 are best 
investigated, showing lower transcriptional activity and lower IL-10 production in 
stimulated whole blood by the ATA haplotype
135
and proposing the rs1800896 as of 
most importance
136
. However, a SNP in the distal promoter (rs1800890) has also 
been suggested functional
137
, and although it is well established that the IL10 gene 
promoter holds functional variants, further investigation of this gene is warranted. 
Studies of the functional properties of the TNFA locus have also been investigated. 
In general there is lack of consistence between studies, and it is to be concluded that 
the regulation of the TNFA locus, which harbors a large number of SNPs in high 
LD, is very complex and that SNPs may have cooperative effect
138
.  The functional 
variants in the IL-4 loci are still not resolved. The CHI3L1 gene is also investigated 
for functional SNPs, and evidence points to variations in the proximal promoter 
region
139
. Similar findings have been published for variations in other key 
inflammatory mediators and further studies of these functional polymorphism are 
awaited
134
.
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CHITINASE-3-LIKE PROTEIN 1 (YKL-40, 
CHI3L1)
The YKL-40 protein, encoded by the CHI3L1 gene, is emerging as a new biomarker of 
severe disease activity and poor prognosis in patients with cancer and autoimmune 
diseases
140
. The functional properties of the CHI3L1 promoter is still under 
investigation. Several polymorphisms are suggested to be functional including the 
CHI3L1 -247G/A (rs10399805) and CHI3L1 -131C/G (rs4950928) 
polymorphisms
141–144
. The exact biological function of the YKL-40 protein is still 
largely elusive. The YKL-40 protein is expressed by various malignant cells and 
tumor associated macrophages and neutrophils
145
. YKL-40 regulates inflammatory 
responses via IL-13Rα2 activating pathways and is involved in apoptosis, oxidative 
injury, pyroptosis, angiogenesis, inflammasome activation and TGFβ mediated anti-
apoptotic signaling as shown in malignant melanoma
146–148
. YKL-40 is regulated by 
IL-1β and IL-6 by activation of  STAT3 / NF-κB pathways, leading to CHI3L1 gene 
transcription and by this YKL-40 protein up-regulation
149
.  To the best of our 
knowledge, no studies have been made exploring the effect of CHI3L1 genotypes in 
B-cell diseases. However, the association to serum levels of the protein have been 
investigated; our group has recently reported that high circulating levels of YKL-40 
is a marker of non-complete remission following salvage therapy before HDT in 
aggressive NHL
114
. Earlier studies have linked plasma levels of YKL-40 to 
prognosis in primary nervous system NHL and Hodgkin’s disease
150,151
. In MM, 
high levels of YKL-40 are associated with high risk disease, and a recent study has 
confirmed this association between serum-YKL-40 and disease risk, increased bone 
resorption and early radiographic progression
152,153
; in RA, YKL-40 is also
associated with disease prognosis
154
.
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METHODS
STUDY POPULATIONS AND SAMPLES
Four different study populations were examined in this thesis:
Study population 1: A Danish RA cohort (Paper I)
Study population 2: A Danish MM cohort (Paper II)
Study population 3: A Danish B-NHL cohort (Paper III) 
Study population 4:  A healthy Danish blood donor population (Paper I, II and III)
Study population 1: 
RA patients were included from the Department of Rheumatology, Hvidovre 
Hospital, Hvidovre, Denmark. The patients were diagnosed with RA according to 
the ACR 1987 criteria
155
. Clinical data from each patient was acquired from the 
DANBIO registry. DANBIO was started in October 2000 and collects clinical data 
from all medically treated Danish RA patients. Three-hundred and eight patients 
were eligible for this study as they fulfilled the diagnostic criteria and had blood 
samples (serum and whole blood) available in the local bio-bank. Blood samples 
were drawn on all patients before the start of treatment with biological drugs.  All 
samples were immediately transported to the lab and handled within 3 hours after 
sampling. Serum and whole blood was subsequent stored at -80°C.
Study population 2
Three hundred forty-eight MM patients were recruited from four participating 
centres in Denmark. All patients were treated with HDT/ASCT. One hundred 
eighty-five patients participated in HDT protocols (Nordic Myeloma Study Group 
(NMSG) no. 5/94, 7/98 and 11/00); the remaining 163 patients were not registered 
in the NMSG protocols, but followed similar treatment regimes
156
. Patients were 
included from August 1994 to August 2004 and the following diagnostic criteria 
where used for inclusion; A: serum monoclonal compartment concentration of 
immunoglobulin IgG > 30 g/L, IgA > 20 g/L, the presence of an M-protein of IgD or 
IgE regardless of concentration, or Bence-Jones proteinuria > 1 g/24 hr; B: M-
protein in serum or urine at a concentration lower than described under A; C: ≥10% 
plasma cells in bone marrow aspirate or biopsy-verified plasmacytoma; and D: 
osteolytic bone lesions. Assignment of diagnosis demanded fulfilling: A + C, A + D, 
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B + C + D. Staging were performed using the Durie and Salmon criteria
157
. 
Biochemical data was available for all patients. OS was calculated from the day of 
diagnosis. For all eligible patients, the following material was available from the 
bio-bank: peripheral blood mononuclear cells (PMBCs) stored at -180°C (292 
patients) and formalin fixed paraffin-embedded (FFPE) bone-marrow samples (56 
patients) taken for routine analysis and stored at room temperature at the local 
department of pathology.
Study population 3.
DLBCL or FL patients diagnosed at Aalborg University Hospital in the period 1999-
2005 was recruited for the study. 216 DLBCL and 139 FL cases were identified. For 
each case, the clinical and biochemistry data was abstracted from the Danish 
lymphoma database (LYFO). Forty-five patients did not have a complete dataset or 
were not registered in LYFO at all. For 32 patients, hospital medical records were 
used to abstract biochemistry and clinical data. Thirteen patients died within a few 
days after diagnosis, and it was not possible to extract sufficient clinical data from 
this small group why they were excluded from survival analysis.  DLBCL and FL
cases were histological classified according to the World Health Organization 
(WHO) classification
74
. The national Danish death registry was used to extract vital 
data on all patients. From all patients, tissue for genotyping was available as FFPE 
BM samples. Included patients did not have dissemination to the BM. All samples 
were initially taken for routine analyses and stored at room temperature at the local 
department of pathology.
Study population 4.
The control group consisted of 605 donors from the Aalborg University Hospital 
blood bank. All donors reported Danish ethnicity and were therefore considered 
Caucasian. The donors routinely sign a statement declaring that they do not take any 
medication and are not under investigation for any disorder. All donors were 
clinically healthy at the time of blood drawing. All samples were handled within 3 
hours after sampling. Serum was separated immediately and stored at -80C. DNA 
was extracted from whole blood within 24 hours and subsequent stored at -80C.
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ETHICAL CONSIDERATIONS
Study population 1
DANBIO has been approved by The Danish Data Registry since the year 2000 (j.nr. 
2007-58-0014 and j.nr. 2007-58-0006) and since October 2006 as a national quality 
registry by the National Board of Health (j.nr. 7-201-03-12/1).
Study population 2
All tissue samples were collected from myeloma patients, healthy controls and BM
donors as described by research protocols N-20100090, and N-20080062MCH, 
respectively. These protocols were approved by the local scientific ethics committee 
of the North Denmark Region.
Study population 3
Research protocols were approved by the local scientific ethics committee of the 
North Denmark Region, approval N-20100059.
Study population 4
Research protocols were approved by the local scientific ethics committee of the 
North Denmark Region, approval N-20090018.
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DNA PURIFICATION
From cryopreserved buffycoat PBMCs, DNA was extracted using a salting-out  
technique where DNA was precipitated with a saturated NaCl solution as described 
in details elsewhere
158
. FFPE samples were cut into five 10 m thick slices.  The 
microtome was cleansed with a biocleaner and 98% ethanol between samples to 
ensure no cross contamination.  Extracting sufficient amount of high quality DNA 
for SNP array analysis was known to be a challenging task, why three methods were 
evaluated thoroughly. An automated standard Maxwell® 16 tissue DNA purification 
method (Promega, Madison, WI, USA) using deparaffinization by heat did not yield 
sufficient DNA for the planned array analyses in study 3. Instead, a manual 
xylene/ethanol method was evaluated for sample preparation. After deparaffinization
by this method, samples were resuspended in ATL buffer (Qiagen) with 0.1 mg/ml 
proteinase K at 56°C overnight and DNA was extracted with the Maxwell® 16 
tissue DNA purification method (Promega, Madison, WI, USA). The manual 
xylene/ethanol yielded higher DNA output, however it was labour intensive and for 
BM samples with low cellular content, did not always prove sufficient DNA yield. 
Finally a novel automated Maxwell® 16 low elution volume tissue DNA 
purification kit (Promega,Madison, WI, USA) was evaluated. Using this kit, FFPE 
tissue was heat-deparrafinized and processed directly using a Maxwell 16 DNA 
purification method based on a magnetic bead separation technique. The process 
was automated on a Maxwell® 16 Instrument. This method proved superior for BM 
samples with low cellular content, and even samples initially discarded were 
reprocessed with favourable DNA outcome. When whole blood samples were 
available, DNA was extracted directly from 200μl ethylenediaminetetraacetic acid 
(EDTA)-stabilized whole blood using Maxwell 16 blood DNA purification kits, 
according to manufactures protocol.  DNA concentration and purity was determined 
using nanodrop 2000 or nanodrop 8000 UV spectrophotometers (NanoDrop 
products, Wilmington, DE 19810 USA). DNA concentration was finally adjusted to 
25 ng/ul for TaqMan single gene analysis or 50 ng/ul for TaqMan open array 
analysis. 
REAL-TIME PCR ASSAY
Real-time polymerase chain reaction (rt-PCR) allows for the monitoring of the PCR 
as it occurs, and the reactions are characterized by the point in time during cycling 
when amplification of a target is first detected. TaqMan based genotyping assay 
were used in all studies 
159–162
. The TaqMan genotyping assays used consists of two 
specific primers (forward and reverse)- see Figure 6 - and two short sequence 
specific minor groove binder (MGB) hydrolysis probes design to discriminate 
between the two polymorphic alleles of the genotyped SNPs amplified within a short 
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PCR product. The specific probes are labeled with two different high-energy 
fluorescent dyes at the 5´ end and termed a reporter. The 3´end is labeled with a 
quencher absorbing the fluorescence from the dyes. When the quencher probe is 
intact and excited by a light source, the reporter dye’s emission is suppressed by the 
quencher dye as a result of the close proximity of the dyes. When the probe is 
cleaved by the 5’ nuclease activity of the enzyme, the distance between the reporter 
and the quencher increases causing the transfer of energy to stop. The fluorescent 
emissions of the reporter increase and the quencher decrease. The fluorescent 
emission can be visualized. With samples of good quality and comparable quantity,
the end-point scatter plot can be used for genotype calling. This allows for allelic 
discrimination between the wildtype homozygous, heterozygous and mutant 
homozygous individuals as illustrated in Figure 7. 
Figure 6. Principles in TaqMan based genotyping assays.
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Figure 7. Allelic discrimination plot. wildtype homozygous (red dots), heterozygous (green dots) and 
mutant homozygous (blue dots) individuals.
TAQMAN SINGLE GENE ASSAY GENOTYPING METHOD                         
(PAPER I AND PAPER II)
SNPs were selected using literature studies and the NCBI SNP database 
(http://www.ncbi.nlm.nih.gov). In Paper I, a total of eight CHI3L1 SNPs were 
genotyped. Four SNPs was located within the promoter region (rs6691378, 
rs10399931, rs10399805, rs4950928) and four SNPs located within the coding 
region of the gene (rs7515776, rs1538372, rs2071579, rs880633). In Paper II, 
thirteen SNPs were selected from the promoter regions of the TNFA, IL4, IL6, IL10, 
and CHI3L1 genes (rs1800795, rs1800630, rs1799964, rs1799724, rs1800629, 
rs361525, rs2243248, rs1800797, rs1800890, rs1800896, rs1800871, rs1800872, and 
rs4950928). Two SNPs (rs1800795 and rs1800630) were genotyped as previously 
described
163,164
. The remaining SNPs were genotyped using available TaqMan SNP 
Genotyping Assays (Applied Biosystems, Foster City, CA, USA). For all assays, 
DNA amplification was carried out in a 5 µl volume containing 20 ng DNA, 0.9 µM 
primers and 0.2 µM probes (final concentrations) and amplified using TaqMan 
Universal PCR Master. A 384-well plate format was used on a GeneAmp PCR 9700 
or a 7900 HT Sequence Detection System. The protocol used were 95°C for 10 
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minutes, followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. To 
determine genotypes, end-point fluorescence was read on the 7900 HT Sequence 
Detection Systems using SDS version 2.3 software (Applied Biosystems, Foster 
City, CA, USA).
TAQMAN OPEN-ARRAY GENOTYPING ASSAY (PAPER III)
A custom SNP array was designed for genotyping. The TaqMan OpenArray 
genotyping system from Applied Biosystems (Applied Biosystems, Foster City, CA, 
USA) uses TaqMan chemistry in a predesigned array. The system was initially 
evaluated and found to provide a high-throughput automated system while allowing 
for high specificity genotyping comparable to single SNP assays. Seven SNPs was 
typed using custom-designed assays and 43 SNPs was typed using predesigned 
TaqMan SNP assays, see Paper III for details. A non-template control (NTC) was 
introduced within each set of assays and TaqMan OpenArray master mix (ABI, 
Foster City, CA, USA) was used in this study according to the manufacture’s 
protocol. Samples were loaded into OpenArray plates using the OpenArray NT 
Autoloader and cycled using GeneAmp 9700 thermal cycler with PCR conditions 
according to the manufacturer’s protocol (ABI, Foster City, CA, USA). The arrays 
were read using the OpenArray NT Imager and the allele calls and scatter plots were 
generated with the Biotrove OpenArray SNP Genotyping Analysis Software 
package version 1.0.3. For all genotyping data the default threshold for the Quality 
value was set to 0.95. The score is an estimate of how closely a given data point 
belongs to those underlying models of angle and amplitude distributions for each 
genotype cluster. The call rate was >80% for all genotypes tested.
AFFYMETRIX GENE EXPRESSION ANALYSIS (PAPER II AND III)
LN tissue, BM samples and DLBCL cells were analyzed as previously described in 
detail
165–167
. Normal LN tissue and BM samples was obtained from healthy 
individuals by routine surgical procedures and was immediately disrupted into 
smaller pieces. Mononuclear cells (MNCs) were enriched using Ficoll-Paque Plus 
(GE Health Care, Uppsala, Sweden) centrifugation before storage in liquid N2 at -
196°C as vital single cell suspensions, frozen in RPMI-1640 medium (GIBCO) 
supplemented with 1% antibiotics, 15% fetal calf serum and 10% dimethyl sulfoxide 
(DMSO) (GIBCO) in a temperature gradient controlled proces
165
. Cells were sorted 
by a FACSAria2 cell sorter directly into 450 µl of lysis/binding buffer (Miltenyi 
Biotech, Bergisch-Gladbach, Germany), using a single tube 8 color antibody panel 
for classification of B-cells. Messenger RNA (mRNA) was isolated and amplified 
using the µMACS mRNA isolation kit (Miltenyi Biotechnologies, Bergisch 
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Gladbach, DE) and the WT-Ovation Pico RNA Amplification System (NuGEN, San 
Carlos, CA, USA) according to the manufacturer’s instructions. Total RNA was 
isolated using a modified TRIzol Reagent protocol (Invitrogen, Paisley, UK) and 
mirVana (Ambion/Invitrogen, Paisley, UK).
165
The samples were prepared for 
hybridization to Affymetrix GeneChip Human Exon 1.0 ST Arrays following the 
manufacturer’s instructions. CEL-files were generated by Affymetrix Gene Chip 
Command Console Software (AGCC) and deposited in the NCBI Gene Expression 
Omnibus (GEO) repository.
165
Retrospective on line available public data on MM 
plasma cell gene expression analysis was available as  mRNA expression profiles in 
CD138-enriched plasma cells from 414 newly diagnosed patients who went on to 
receive HDT and tandem stem cell transplants.
168
Gene expression data was 
analyzed using Partek Genomics Suite version 6.5 (Partec Inc., St. Louis, MO, 
USA). 
BIOCHEMICAL ANALYSIS (PAPER I)
The YKL-40 serum concentration was measured using a commercial two-site 
sandwich type ELISA (Quidel, Mountain View, CA, USA). For this assay, the 
detection limit was 10 ng/ml. The intra-assay coefficient of variations (CV) was 5% 
and the inter-assay CV was < 6%
154
. 
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STATISTICS
Statistical analyses were carried out using the statistical software R R-3.2.0
(http://www.r-project.org/) and STATA  version 12.1 (StataCorp, Texas, USA), 
Helix Tree SNP analysis software package (Golden Helix Software, Bozeman, MT, 
USA) and SHEsis software (Bio-X Center, Shanghai Jiao Tong University,1954 
Huashan Road, Shanghai 200030, China).
HARDY-WEINBERG EQUILIBRIUM
SNPs in the control group were in all studies tested for Hardy-Weinberg equilibrium 
(HWE) using Helix Tree SNP analysis software package. Deviations from HWE in 
the control group lead to exploration of genotyping quality, and eventually retesting 
of samples. Deviation from HWE in the patient cohort was an expected 
phenomenon. Calculation was made by calculating the expected and observed allele 
frequencies using the Hardy-Weinberg theorem: (p + q)
2
= p
2
+ 2pq + q
2
= 1 
representing alleles with the frequencies p and q. A chi-square test with 5% 
significance level was subsequently applied to test deviation from HWE.
LINKAGE DISEQUILIBRIUM 
The degree of LD between SNPs known to be located in haplotype blocks was 
determined using the SHEsis software. Findings were compared to data acquired 
from the international HapMap project database (http://hapmap.ncbi.nlm.nih.gov/). 
LD were reported as the disequilibrium coefficient D’ explaining the quantitative
deviation of the observed frequency of a haplotype from the expected. The 
correlation coefficient r
2
further include the allele frequencies in the calculation 
since this can be of importance if rare alleles are included in the calculation
169
.
MODELING THE GENOTYPE EFFECT ON SERUM PROTEIN LEVELS 
The serum YKL-40 protein concentrations were log transformed resulting in normal 
distribution in patients and controls. A non-linear and a linear model were explored 
to adjust for the age-dependent increase in YKL-40. The linear model was 
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acceptable and included in a multiple linear regression model containing case-
control status, age, gender, genotypes and YKL-40 concentration. This analysis 
further included interactions between explaining variables, and this model could 
then define independent factors associated with serum concentration. The effect of 
individual genotypes was explored by including the genotypes one-by-one as 
dependent variables in a linear age-adjusted model. The most significant SNP was 
then used as a covariate to determine the influence of the remaining SNPs.
CORRECTION FOR MULTIPLE COMPARISONS
When appropriate, we used correction for multiple comparisons to exclude over-
interpretation of results.  With an increasing number of comparisons in the analysis, 
it becomes more likely to observe differences between groups by random chance 
alone. Since strict correction unfortunately also holds a risk of discarding important 
findings as random variation, this aspect should be considered before implying 
correction and should be avoided in explorative studies
170
. In the initial approach of 
single SNP associations we used uncorrected statistics. However, in gene-gene 
interaction analyses and gene-expression analyses we decided to apply a strict 
correction for multiple comparisons using the conservative Bonferroni method. In 
praxis, the significance level used in single comparison analysis (0.05) was divided 
by the number of comparisons. As an example if 23 genes were compared we used a 
significance level of 0.05/23 = 0.0022.
GENOTYPE MODELS
We analyzed each SNP in three different ways, namely using additive, wild type, 
and variant models. The three genotypes of each SNP are kept in the additive model. 
In contrast, the wild type and variant models have two levels per SNP. For example, 
for TNFA -863C/A, C is the most common allele. Accordingly, the additive model 
compares CC, CA, and AA, the wild type model compares CC and CA + CC, and 
the variant model compares AA and CA + CC.
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ANALYSIS OF CASE-CONTROL DATA
The effect on individual SNPs  and haplotypes was estimated as an odds ratio (OR): 
The association between disease status and various explaining variables were
quantified by odds ratios (OR) using logistic regression models. The regression 
model was used to estimate the associations between disease status and single 
genotypes, haplotypes, and the interactions between SNPs and between haplotypes
171
. The significance of individual variables was assessed by likelihood ratio tests 
that compared the model with and without the variable using the anova.glm function 
in the stats package. 
SURVIVAL ANALYSIS
An important component of survival data analyses is the Kaplan-Meier estimator for 
generation of Kaplan-Meier survival curves which give a valuable visual impression 
of the effect of genotypes on survival. Patients were stratified according to genotype, 
survival time was calculated from time of diagnosis until death or censoring. In case 
of comparison of survival curves for two or more groups we used the non-
parametric log rank test. The Kaplan-Meier curves with log rank test were used to 
describe differences in OS between genotype groups; however, to include the effect 
of more variables on survival, the Cox proportional hazard model was applied. Cox 
proportional hazard model was used to generate hazard ratios for a specified 
outcome (death) between individuals with different characteristics (genotypes, sex, 
prognostic score, etc.). The survival model are reported as hazard ratios (HRs) 
adjusted for significant prognostic factors with 95% CI and p-values 
171
. 
GENE-GENE INTERACTION MODEL
The purpose of performing gene-gene interaction analyses was to identify pairs of 
genes for which the interaction between them was significantly associated with the 
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risk of lymphoma diagnosis (performed by logistic regression) or significantly 
associated with survival among lymphoma patients (performed by Cox regression). 
We performed the gene-gene interaction analyses by comparing the models with and 
without the interaction term using a likely hood ratio test. Highly significant 
interactions were selected using the p-value from the likely hood ratio test as 
proposed by Cordell,
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by comparing the saturated model including interaction and 
additive effects with the purely additive model. We corrected for the number of 
individual loci (31 loci) investigated, why only interactions with a p-value of < 
0.002 were considered significant. As 9 possible combinations of genotypes exist for 
each pair of genes, we have for the survival part reported hazard ratio estimates for 
each combination of genotypes with the combination of the most frequent 
homocygotes as reference. 
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RESULTS AND DISCUSSIONS
PAPER I
Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum 
concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy 
subjects
AIM AND DESIGN
This Paper aimed to establish a method for evaluating the functional effect of SNPs 
in the CHI3L1 gene in relation to the pro-inflammatory YKL-40 protein and explore
if this gene had pathogenetic impact in RA. This was evaluated by genotyping a 
cohort of RA patients (study population 1) and a cohort of healthy blood donors 
(study population 4). We investigated 8 SNPs in the CHI3L1 gene and measured
serum levels of YKL-40.
RESULTS AND DISCUSSIONS
Investigation of serum YKL-40 levels in both populations revealed no difference 
with respect to gender, however, serum levels increased with increasing age. After 
log transformation, serum YKL-40 levels were found to be normally distributed and 
up till the age of 65, the association between age and serum YKL-40 was linear why 
we decided to included only persons <= 65 years. When testing each genotype 
individually the -131C/G (rs4950928) SNP was most strongly associated with YKL-
40 levels in patients (p=2,4e-08) and controls (p= 2.2e-16). A dose effect of the 
genotypes was found, establishing the G allele as low producer and C allele as high 
producer as shown in Figure 8 (Paper I, Figure 3)
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Figure 8. Association between the CHI3L1 -131C/G (rs rs4950928) SNP and serum concentrations of 
YKL-40. Box plot for 238 patients with rheumatoid arthritis (RA) ≤ 65 years of age (P < 2.0e-16 and 605 
healthy controls (P < 1.1e-8). The x-axis represents genotypes. The y-axis represents serum YKL-40, 
horizontal bars represents median serum YKL-40 and quartiles for patients with RA and controls.
In this study we did not find any association between genotypes or haplotypes and 
the risk of developing RA. The -131C/G (rs4950928) allele have earlier been
associated with YKL-40 expression by Zhao et al. who studied CHI3L1 gene 
expression in a small study of 29 schizophrenic patients and 54 controls, they also 
found lower activity of transcriptional factor activity associated with this SNP
141
.
Ober et al. reported association between several SNPs in the CHI3L1 gene and 
serum YKL-40, due to very high LD it was difficult to explore further into the exact 
functional SNP
173
. Sohn et al reported the -247G/A (rs10399805) SNP associated 
with serum YKL-40 levels in an Asian population, however allele frequencies and 
LD was different from Caucasian populations, clearly emphasizing the problem in 
extrapolation genetic findings between ethnically different populations. Our findings 
have subsequent been confirmed in a large Danish cohort
142
and an US cohort
174
both suggesting a pronounced functional effect of the -131C/G (rs4950928) allele. 
We therefore suggest that this SNP must be included in future association studies if 
the functional aspects of the CHI3L1 promoter is to be studied in relation to disease 
risk or outcome.
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LIMITATIONS AND METHODOLOGICAL CONSIDERATIONS
We studied an ethnically homogenous but relatively small cohort. The sample size 
results in relatively few persons with the homozygous mutant genotype affecting the 
strength of the study. Moreover, the CHI3L1 locus seem to have different allele 
frequencies and LD between different ethnic groups why our findings may only be 
valid in a north European Caucasian cohort. We did not include a functional assay to 
determine if the region close to the -131C/G (rs4950928) SNP is actually the 
binding site for transcription factors and if transcription could be blocked by 
interfering with this specific area of the promoter, as suggested by a few 
investigators
139
. This clearly needs to be studied in more detail before we can 
conclude on the functional properties of this locus. Another puzzle is the fact that 
although genotypes and a number of autoimmune and malignant disease seem to be 
independently associated with serum YKL-40 levels, the direct association between 
genotypes and disease has been less clear
174,175
and must be explored in future
studies. 
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PAPER II
Interactions between inherited inflammatory response genes are associated with 
multiple myeloma disease risk and survival.
AIM AND DESIGN
In this Paper we aimed to explore if genetic variation in cytokine genes CHI3L1,
TNFA, IL4, IL6 and IL10 was of pathogenetic impact in MM. We investigated a 
cohort of MM patients (study population 2) and a healthy control group (study 
population 4)
RESULTS AND DISCUSSIONS
The -238A (rs361525) allele was associated with decreased MM risk (OR=0.51 
(0.29-0.86)) suggesting that low producer TNFA genotypes
176
may protect against 
the development of MM. Association between MM and the TNFA -238A allele was
however not reported in two earlier studies including 181 Caucasian MM patients 
and 210 Asian MM patients
55,177
. The TNFA -308G/A polymorphism has been 
associated with MM in British and Hungarian patients
55,57
. We did not find this 
association in our Danish study population, supporting the findings by Zheng et al. 
and the recent meta-analysis by Vangsted et al.
53,61
. We examined the prognostic 
effect of genotypes and found the TNFA -857 and IL10 -1082 SNPs highly 
associated with 5 year OS. IL-6, IL-4, IL10 and TNFα are individual B-cell 
proliferation factors and may work in a network
3
. Gene-gene interaction analysis 
revealed impact of IL6, IL10, TNFA and IL4 genotypes on OS, see Figure 9 (Paper
II, Figure 1C) and Figure 10. (Paper II, Figure 1D) 
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Figure 9. Association between 5-year overall survival and genotypes. Hazard ratios (HR) was adjusted 
for sex, age, Durie-Salmon stage, creatinin, and β2-microglobulin. IL6 -174G/C and IL10 -3575T/A 
genotypes on OS. HRGG*AA=3.17 (1.69-5.94), P=0.007. 
Figure 10. Association between 5-year overall survival and genotypes. Hazard ratios (HR) was adjusted 
for sex, age, Durie-Salmon stage, creatinin, and β2-microglobulin. TNFA -308G/A and IL4 -1098T/G
genotype. HRAA/AG*GG/GT=3.47 (1.64-7.37), P=0.03.
The findings of these interaction is very interesting but also difficult to interpret as 
the functional aspects of these individual SNPs still remain partly elusive
134
. The
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existence of premalignant B-cells with a memory phenotype harboring IgH 
translocation have been described in MM
22
. We found TNFA, IL6 and CHI3L1
genes up regulated in normal memory B-cells suggesting that cytokine genes in 
these B-cell subsets may play a role in premalignant transformation. CHI3L1, IL6
and IL10 gene expression in MM cells was also significantly associated with 
prognosis when assigned to the TC classification system (Figure 11), indicating that 
these inherited genetic variants may play a role in response to treatment. Interaction 
between IL6 and IL10 was also seen at expression level supporting our findings 
from the SNP studies. 
             
       
Figure 11. Gene expression in enriched MM cells from patients grouped in poor and good prognosis 
based on TC classes. (A) CHI3L1 gene expression, (B) IL10 gene expression and (C) IL6 gene 
expression.
The functional CHI3L1 SNP (Paper I) was not associated with risk of MM and no 
association with outcome was seen in univariate analysis.  We did observe highly 
A B
C
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significant interaction between the CHI3L1 genotypes and TNFA and IL10. Due to 
low number of patients in the rare allele group we could, unfortunately, not obtain 
precise risk estimates. We believe the CHI3L1 gene needs further investigation in 
MM.
LIMITATIONS AND METHODOLOGICAL CONSIDERATIONS
Our results add another layer to the complexity of the roles of cytokines in MM by 
suggesting that gene-gene interactions must be included when analyzing the effect 
of cytokine genes. This approach needs to be considered in design of such studies to 
ensure statistical power for these investigations. Our study cohorts were uniform 
with regards to ethnicity, and the genotyping method used gives a high call-rate and 
very high allele specificity. However, our sample size was too small with regards to 
in depth study of rare alleles and gene-gene interactions. Inconsistence between 
studies on risk and prognosis genes is a major challenge
52,53
. We observed small 
sample size in some of these earlier studies, and ethnic differences make direct 
comparisons difficult. With regard to sample size and the “curse of dimensionality”
using regression based interaction analysis, we did explore other statistical methods 
as multifactor dimensionality reduction (MDR)
178
for evaluation of gene-gene 
interactions, however, these methods are still under development. This emphasizes
the important role for biostatisticians in genetic research.  Future studies should 
address these problems and must include functional analyses of the respective 
genetic loci, as we discovered that the functional knowledge of these genes is rather 
sparse. 
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PAPER III 
Inherited inflammatory response genes are associated with B-cell non-Hodgkin’s 
lymphoma risk and survival.
AIM AND DESIGN
We aimed to investigate if genetic variation in 50 highly selected and interacting 
cytokine genes was of pathogenetic impact in B-NHL. We investigated a cohort of 
B-NHL patients (study population 3) and a healthy control group (study population 
4).
RESULTS AND DISCUSSIONS
The case-control study revealed two major findings; an effect of genes encoding 
inflammatory mediators known to act as B-cell proliferation and differentiation 
factors such as IL1-β, IL-10 and TLR9 and an effect of genes located in the HLA-II 
region (TAP2) confirming the importance of genes in this region for lymphoma 
risk
179
. A novel finding was that the TAP2 SNP was also associated with DLBCL 
prognosis and this high LD region needs further studies before the exact gene/genes 
related to this increased risk are identified and the functional mechanisms 
established
89,91,180
. We have recently reported serum levels of the YKL-40 protein 
associated with outcome in NHL
114
.  In the present study we observed outcome 
associated with a functional CHI3L1 genotype in FL as shown in Figure 12 (Paper 
III, Figure 1A) and although this further strengthens a suggested effect of this 
inflammatory protein in B-lymphomas, this needs further investigation.
Figure 12. Association between FL 10 year overall survival and CHI3L1 (rs4950928). HRCG = 2.04 
(1.17-3.54).
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An interaction between IL4 and IL10 loci were of prognostic significance. The
isolated effect of IL10 and IL4 polymorphisms is somewhat contradictory
throughout the literature (see Paper IV), however, these inflammatory mediators 
play a major role in the GC reaction. B-cell proliferation is enhanced by IL-10 in the 
presence of IL-4 and both cytokines are involved in the CSR procees
33,181,182
. We 
found that carriers of the IL10 (rs1800890) AA in combination with the IL4RA
(rs1805010) AA genotype had a significantly improved OS (HR=0.11 (0.20-0.50)). 
The rs1805010 polymorphism is a 'gain-of-function' mutation, which results in 
substitution of isoleucine for valine (I75V) in the extracellular domain of IL-4Rα 
subunit. The G variant results in abnormal activity of the STAT6 transcription factor 
even without IL-4 stimulation
183
. IL-10 has earlier been proposed as an important 
proliferation factor for lymphoma cells and gene expression of the IL10 gene has 
been shown in FL and IL10RA in Waldenström's macroglobulinemia.
184
Results of 
gene expression analyses are shown in Figure 13.
Figure 13. Gene expression analysis of the IL10, IL10RB, IL4 and IL4RA genes. The (*) represents 
significant difference in expression after Bonferroni correction. Gene expression is presented on a log2 
scale. Lymphoma: DLBCL B-cells, N: Naïve B-cells, CC: Centrocytes, CB: Centroblasts, PB: 
Plasmablasts, M: Memory B-cells.
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We found an up-regulation of the IL10 and the IL10RB gene in DLBCL cells when 
compared to normal GC B-cell subpopulations. This supports a role for these 
cytokines in the pathogenesis of GC derived lymphomas, as supported by earlier 
findings in chronic lymphocytic leukemia (CLL)
185
. These findings add functional 
support to the reported protective effect of the low producer IL10 (rs1800872) AA 
genotype as well as the protective effect of the IL10RB (rs1058867) G allele
82,186
. 
The decreased expression of  the IL4 gene in DLBCL cells and the lower expression 
of the IL4R gene in post GC B-cell subpopulations suggest an effect of these genes 
at different stages of the oncogenetic process in B-cell malignancies
103
, and that such 
genes might be important in the multi step process of malignant transformation even 
if they are not found to be expressed in malignant tissue
21
. Although these data need
confirmation in future studies, these two cytokines seem to interact in relation to 
both risk and outcome. The functional properties of these pathways obviously need
further investigation; as an example, the functional properties of IL4 gene and the 
distal IL10 promoter still remain largely unknown as does the effect of these 
interactions on protein level
134
. 
LIMITATIONS AND METHODOLOGICAL CONSIDERATIONS
Our results were not always consistent with findings in other B-NHL cohorts. This 
can be a result of small sample sizes as well as ethnical differences between study 
populations. Our patient cohort was ethnically homogenous with a long follow up 
period. However, our sample size was under powered for gene-gene interaction 
analyses making exploration of cytokine networks difficult. Expanding analyses 
beyond two-way interaction would require a larger patient cohort. Non-regression 
based statistical methods could also be considered. Another limitation is the lack of 
functional knowledge for a number of the genes analysed. The age distribution in the 
control group and patient group was not identical, and the sample material differed 
between groups. We found no association between age and genotypes within the 
groups, and we included a cohort with no reported BM involvement; however, these 
differences between groups still could have introduced bias to our results. Since 
DLBCL has been shown to consist of different subtypes with regard to gene 
expression profiles, this also needs to be considered in future genetic studies.
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PAPER IV
Inherited variation in immune response genes in follicular lymphoma and diffuse 
large B-cell lymphoma.
AIM AND DESIGN
We aimed to review the literature to investigate the current knowledge with respect 
to SNPs in immune regulatory genes in the pathogenesis of B-NHL with focus on 
the use of the candidate gene approach, the GWAS approach and the pathogenetic 
effect of gene-gene interactions.
RESULTS AND DISCUSSIONS
After a MESH driven literature search strategy, abstracts were evaluated and 89 
Papers were finally included for review. Of these Papers, the majority was related to 
disease risk (63 Papers) whereas 26 Papers explored genes in relation to outcome.
In brief, we discovered that polymorphisms in the TNFA and IL10 loci were 
relatively consistently associated with DLBCL risk. Variations in the HLA class I 
loci at chromosome 6p31-32 were associated with FL risk. In addition variations in 
the TNFA locus were associated with DLBCL outcome. Although clear differences 
seem to exist for genetic susceptibility between FL and DLBCL, genes in the HLA-
TNFA-LTA region on chromosome 6 seem to be a common risk factor in both 
lymphoma subtypes. GWAS studies will in the future detect many novel genes 
associated with lymphoma. However, this approach must be combined with 
carefully designed candidate gene studies, exploring functional properties of 
investigated genotypes and providing sufficient coverage of the investigated genes.
Ethnic differences, effects of rare variants and gene-gene interactions must be 
included when planning future studies.
LIMITATIONS AND METHODOLOGICAL CONSIDERATIONS
Studies were generally heterogeneous in terms of size, ethnic groups, included 
SNPs, genotyping methods and statistical methods making direct comparison 
difficult. Functional studies of the investigated genotypes only rarely exist; however,
52
it would have strengthened our review if functional properties were discussed in 
depth. We could also have missed studies in our search strategy, and in general, a 
publication bias could be present. Since minor changes in the expression of genes 
and the effect of gene-gene interactions can have dramatic effects, these factors need
to be addressed in further studies.; it was not possible to thoroughly
review these aspect of genotype/phenotype associations in the present review. 
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CONCLUSIONS
The research presented in this thesis can be summarized in the following 
conclusions:
In our first study we established genotyping methods for exploring the functional 
properties of the CHI3L1 gene promoter. Furthermore, we discovered a functional 
SNP strongly associated to serum levels of the proinflammatory YKL-40 protein, a 
known marker for RA and MM disease activity
140,153,154
and as we recently 
published, a marker of remission status in NHL
114
. We do acknowledge that our 
cohorts were small, however, after our studies were published, other groups have 
explored this functional SNP and confirmed our findings
142,174
. The combination of 
in vivo functional studies as ours and in vitro functional studies of CHI3L1 gene 
transcription clearly points to the -131C/G rs4950928 as a functional SNP. The 
direct association between this SNP and autoimmune or malignant disease seem less 
obvious
144,173,175,187
; we did not find association between the CHI3L1 gene and RA, 
which was later reproduced
175
. The evidence could suggest, that in inflammatory 
diseases as RA, the high YKL-40 level is a consequence of the inflammatory 
process itself more than a causal factor, whereas in malignant diseases CHI3L1
genotypes may be part of a disease risk genotype
187
. In hematological malignancies 
the effect of CHI3L1 genotypes is only scarcely investigated, however, our studies 
propose the needs for investigation in diseases where YKL-40 expression seems to 
be of prognostic impact
114,150–152
.
In the second study, we evaluated the pathogenetic effect of proposed functional
cytokine SNPs in MM. We found low producer TNFA genotype associated with 
decreased disease risk, in accordance with some, but not all earlier findings
55–57,61
.
Discrepancy between studies of different sample size, patient characteristics, 
ethnicity, and methods is well known
134,188,189
, and we argue for confirmatory studies 
sufficiently powered and of multicenter design. External validity is a general 
challenge in genetic studies as they are often only reproducible in the exact same 
ethnic groups. Cytokines are expected to be part of a network and not just acting as 
single independent factors
3,190
why we established a method for studying interactions 
between pathogenetic genes. Interaction on gene level has been suggested by some 
authors
178,191–195
, and we did find disease outcome related to gene interaction. We 
were, however, not able to study high order interactions as our sample size was too 
small to acquire sufficient statistical power. We hypothesized that these 
inflammatory response genes were of pathogentic impact. We therefore included 
gene expression analyses of these selected genes in normal B-cell subpopulations 
and malignant PCs. We were able to display different expression patterns 
confirming a possible effect of these genes. To further support these findings we 
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included a retrospective MM cohort of 414 patients and found that expression of the
IL6, IL10 and CHI3L1 genes were related to prognostic TC classes. We argue that 
these inflammatory response genes interact and that the effect of them goes beyond 
pure paracrine stimulatory effects.This has not been investigated earlier and clearly 
needs confirmation as our study is a small scale explorative study. 
In the third study we established a method for using routine FFPE BM samples in
SNP array analyses. Extracting sufficient high quality DNA from stored samples is 
known to be difficult why we evaluated three different methods before deciding on a 
novel automated method. We then tested 50 highly selected SNPs and investigated 
single genes, haplotypes and gene-gene interactions. We discovered several novel 
associations, for example the CHI3L1 (rs4950928) associated with disease outcome 
in FL. Moreover, we confirmed earlier findings with regards to SNPs in the TNFA
and HLA region. Interaction analyses pointed to the importance of IL-10 and IL-4
related genes in DLBCL. We also found these genes differently expressed between
different B-cell compartments and DLBCL cells. This supports a role for these 
genes in the step-wise oncogenetic process and suggests that functional aspects 
should be investigated in the B-cell hierarchy using a “cell of origin” approach. We 
did not always find results consistent with earlier findings and therefore decided to 
review the literature of inherited genetic variation in relation to FL and DLBCL. We 
found some consistence for genes in key inflammatory mediators as TNFA, IL10 and
HLA, however, we conclude that both novel GWAS studies and carefully designed 
candidate genes studies are needed to explore new and confirm suspected risk 
alleles. Moreover, the functional aspects of many SNPs still remain elusive needing
further studies. Gene-gene interactions are important factors in future studies and 
biostatistical expertise are required in the study designs.
55
PERSPECTIVES
In RA, MM, DLBCL and FL inherited variations in inflammatory response genes 
seem to have pathogenetic impact
14,44,196
. We added new knowledge to this 
assumption by studying effects of a novel functional CHI3L1 variant, and we 
investigated the expression of these proposed pathogenetic genes in different B-cell 
subpopulations. We propose an effect of inherited variants in inflammatory 
tumor/host reaction as well as in direct inherited genetic hits in the process of 
malignant transformation. Interactions between genes could explain the difficulty in
predicting a phenotype from single genotypes, as the system is extremely complex.
Combinations of corticosteroids and chemotherapeutic agents have for decades 
remained the backbone of treatment in MM, NHL and even RA. However in recent 
years, novel diagnostic approaches using high resolution genetic analysis instead of 
classic caryotyping  together with a broad range of newer treatments as
immunomodulatory drugs, cytokine inhibitors, monoclonal antibodies and 
proteasome inhibitors  has been introduced
14,39,197
. Such development can only be 
achieved by knowing more about the biology in B-cell diseases; genetic analyses 
could be part of the solution towards true personalized medicine. We have already 
learnt more about pathogenetic genes from GWAS studies than would have been 
possible by hypothesis driven studies alone. The combination of biological driven 
research and the hypothesis free whole genome studies promise new knowledge in 
the coming years. Future options, including next generation sequencing, miRNA
analyses and epigenetic analyses may prove a way to achieve more insight in the 
biology of B-cell diseases. The findings of cytokine genes being expressed in both 
diseased tissue and normal microenvironment argues for a more broad effect of 
these genes by changing signaling mechanisms and providing genetic hits leading a 
normal B-cell towards a pathogentic pathway. These same genes may also affect the 
microenvironment and provide a niche for the pathogenetic cells
196
. Genetic studies 
are typically difficult to interpret due to inconsistence; small study populations are
included, techniques differ and the ethnicity of study populations differ - challenges
we have faced in our own studies. Novel genotyping approaches, statistical methods 
and consortium driven analyses as the Myeloma Genetics International Consortium 
(MAGIC) 
198
, the International Lymphoma Epidemiology Consortium 
(InterLymph)
82
and the Wellcome Trust Case Control Consortium
47
now promise
the insight we lack from earlier smaller studies. When designing novel studies it is 
important to have enough resolution in the techniques used to study rare variants. 
Gene-gene interaction analyses are required to account for the fact that cytokines act 
in networks
3,189
. We then need to address the functional properties of these genetic 
variants through in vitro and in vivo model systems. This may clarify associations 
between proposed pathogenetic variants and gene-expression, protein expression, 
splicing and epigenetic modifications
134,199–201
. These models must include cells 
believed to represent normal counterparts of the pathogenetic cells and different 
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pathogenetic cell lines in combination with in vivo studies of protein expression 
between individuals with variant genotypes
19,54,166,202,203
.  The ultimate goal of our 
studies is true personalized therapy, first allowing for correct prognostic evaluation 
and then applying the right drug in the right dose for the right patient. We have 
taken the first step towards this direction in DLBCL
204
and have planed future 
studies both as participants in consortium based genetic studies, in vivo studies of 
cytokine expression in healthy individuals and persons with B-cell diseases and in 
vitro studies of gene- and protein expression in various cell lines and normal tissue. 
We believe that these approaches will bring us a more detailed knowledge of the 
complex biology of B-cell diseases and through this a more rational prognostic 
classification and treatment strategy.
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